Cargando…

Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis

Objectives. To demonstrate the pharmacokinetic equivalence of CT-P13 and its innovator infliximab (IFX) in Japanese patients with rheumatoid arthritis (RA), and to compare the efficacy and safety of these drugs, administered for 54 weeks. Methods. In a randomized, double-blind, parallel-group, multi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takeuchi, Tsutomu, Yamanaka, Hisashi, Tanaka, Yoshiya, Sakurai, Takeo, Saito, Kazuyoshi, Ohtsubo, Hideo, Lee, Sang Joon, Nambu, Yoshihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4732515/ https://www.ncbi.nlm.nih.gov/pubmed/25736355 http://dx.doi.org/10.3109/14397595.2015.1022297

Ejemplares similares

Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2)
por: Tanaka, Yoshiya, et al.
Publicado: (2008)

Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study
por: Tanaka, Yoshiya, et al.
Publicado: (2015)

Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients—REACTION 52-week study
por: Takeuchi, Tsutomu, et al.
Publicado: (2011)

Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54
por: Alten, Rieke, et al.
Publicado: (2019)

Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study
por: Koike, Takao, et al.
Publicado: (2011)

Remission induction by Raising the dose of Remicade in RA (RRRR) study: Rationale and study protocol for a randomized controlled trial comparing for sustained clinical remission after discontinuation of infliximab in patients with rheumatoid arthritis
por: Oba, Koji, et al.
Publicado: (2017)

Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results
por: Smolen, Josef S., et al.
Publicado: (2017)

Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study)
por: Yamanaka, Hisashi, et al.
Publicado: (2010)

Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study
por: Park, Won, et al.
Publicado: (2016)

Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial
por: Yamanaka, Hisashi, et al.
Publicado: (2014)

Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY(®) compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials
por: Takeuchi, Tsutomu, et al.
Publicado: (2023)

Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study
por: Tanaka, Yoshiya, et al.
Publicado: (2014)

Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial
por: Tanaka, Yoshiya, et al.
Publicado: (2016)

Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1 year outcomes of the HOPEFUL-2 study
por: Tanaka, Yoshiya, et al.
Publicado: (2016)

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
por: Fasanmade, Adedigbo A., et al.
Publicado: (2009)

Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study)
por: Takeuchi, Tsutomu, et al.
Publicado: (2011)

Reconstitution of disrupted photoreceptor layer in uveitis associated with Behçet’s disease by infliximab treatment
por: Takeuchi, Masaru, et al.
Publicado: (2015)

Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks
por: Takeuchi, Tsutomu, et al.
Publicado: (2013)

Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study
por: Tanaka, Yoshiya, et al.
Publicado: (2017)

A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study
por: Yoo, Dae Hyun, et al.
Publicado: (2016)

Physiologically‐Based Pharmacokinetic Modeling vs. Allometric Scaling for the Prediction of Infliximab Pharmacokinetics in Pediatric Patients
por: Malik, Paul R. V., et al.
Publicado: (2019)

A descriptive analysis of real-world treatment patterns of innovator (Remicade(®)) and biosimilar infliximab in an infliximab-naïve Turkish population
por: Yazici, Yusuf, et al.
Publicado: (2018)

External Evaluation of Population Pharmacokinetic Models and Bayes-Based Dosing of Infliximab
por: Konecki, Celine, et al.
Publicado: (2021)

Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study
por: Yamanaka, Hisashi, et al.
Publicado: (2016)

Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan
por: Takeuchi, Tsutomu, et al.
Publicado: (2015)

Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients
por: Takeuchi, Tsutomu, et al.
Publicado: (2018)

Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab
por: Yazici, Yusuf, et al.
Publicado: (2018)

Pharmacokinetic equivalence study of two formulations of the anticonvulsant pregabalin
por: Tjandrawinata, Raymond R, et al.
Publicado: (2015)

Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study)
por: Kaneko, Yuko, et al.
Publicado: (2016)

Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies
por: Genovese, Mark C., et al.
Publicado: (2021)

Cataract Surgery in Behçet's Disease Patients One Week after Infliximab Administration
por: Handa, Tsuneaki, et al.
Publicado: (2011)

Trabeculotomy in a Behçet's Disease Patient One Week after Infliximab Administration
por: Koike, Aya, et al.
Publicado: (2012)

74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis
por: Delabaye, Isabelle, et al.
Publicado: (2010)

Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
por: Mulleman, Denis, et al.
Publicado: (2011)

Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation
por: Magro, Fernando, et al.
Publicado: (2017)

Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients
por: Koike, Takao, et al.
Publicado: (2011)

The testosterone-dependent and independent transcriptional networks in the hypothalamus of Gpr54 and Kiss1 knockout male mice are not fully equivalent
por: Prentice, Leah M, et al.
Publicado: (2011)

Pharmacokinetic equivalence study of nonsteroidal anti-inflammatory drug etoricoxib
por: Tjandrawinata, Raymond R, et al.
Publicado: (2018)

Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose–response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)—a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial
por: Takeuchi, Tsutomu, et al.
Publicado: (2016)

Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study
por: Ishiguro, Naoki, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_u3383gu4vuc72iajtfch2rbils